Search

Your search keyword '"Amutio, Elena"' showing total 46 results
Start Over Author "Amutio, Elena"
46 results on '"Amutio, Elena"'

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Author

Lakhwani, Sunil, Mateos, María Victoria, Martínez-López, Joaquín, Paiva, Bruno, Rosiñol Dachs, Laura, Martínez, Rafael, Oriol, Albert, Bargay, Joan, González-Montes, Yolanda, Gironella, Mercedes, Encinas, Cristina, Martín, Jesús, Jarque, Isidro, Granell, Miquel, Abella, Eugenia, García-Mateo, Aránzazu, Hernández-Rivas, José Ángel, Ramila, Elena, Krsnik, Isabel, Casado Montero, Luis Felipe, De Arriba, Felipe, Palomera, Luis, Sampol, Antonia, Moraleda, José María, Casanova, María, Delgado, Pilar, Lafuente, Ana, Amutio, Elena, López-Martínez, Aurelio, Altés, Albert, Ruíz, M. Ángeles, Alegre, Adrián, Lopez-Anglada, Lucia, De La Cruz, Javier, Alonso Fernández, Rafael, Bladé Creixenti, Joan, Lahuerta, Juan-José, San-Miguel, Jesús, and Hernández, Miguel-Teodoro

Published
2024
Full Text
View/download PDF

3. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

Author

Fundación Piel Sana, Academia Española de Dermatología y Venereología, Kyowa Hakko Kirin, Muniesa, Cristina, Gallardo, Fernando, García-Doval, Ignacio, Estrach, M. Teresa, Combalia, Andrea, Morillo Andújar, Mercedes, Cruz-Vicente, Fátima de la, Machan, Salma, Moya-Martínez, Cristina, Rovira, Roger, Sánchez-González, Blanca, Acebo, Elvira, Amutio, Elena, Peñate, Yeray, Losada-Castillo, Maria Del Carmen, García Muret, María Pilar, Iznardo, Helena, Román-Curto, Concepción, Cañueto, Javier, Fernández de Misa, Ricardo, Flórez, Ángeles, Izu, Rosa María, Torres-Navarro, Ignacio, Zayas, Ana, Pérez-Paredes, Gema, Blanes, Mar, Yanguas, J. Ignacio, Pérez-Ferriols, Amparo, Callejas-Charavia, Marta, Ortiz-Romero, Pablo Luis, Pérez-Gil, Amalia, Prieto-Torres, Lucia, González-Barca, Eva, Servitje, Octavio, Fundación Piel Sana, Academia Española de Dermatología y Venereología, Kyowa Hakko Kirin, Muniesa, Cristina, Gallardo, Fernando, García-Doval, Ignacio, Estrach, M. Teresa, Combalia, Andrea, Morillo Andújar, Mercedes, Cruz-Vicente, Fátima de la, Machan, Salma, Moya-Martínez, Cristina, Rovira, Roger, Sánchez-González, Blanca, Acebo, Elvira, Amutio, Elena, Peñate, Yeray, Losada-Castillo, Maria Del Carmen, García Muret, María Pilar, Iznardo, Helena, Román-Curto, Concepción, Cañueto, Javier, Fernández de Misa, Ricardo, Flórez, Ángeles, Izu, Rosa María, Torres-Navarro, Ignacio, Zayas, Ana, Pérez-Paredes, Gema, Blanes, Mar, Yanguas, J. Ignacio, Pérez-Ferriols, Amparo, Callejas-Charavia, Marta, Ortiz-Romero, Pablo Luis, Pérez-Gil, Amalia, Prieto-Torres, Lucia, González-Barca, Eva, and Servitje, Octavio

Abstract

[Background] Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited., [Objectives] To evaluate the response and tolerance of BV in a cohort of patients with CTCL., [Methods] We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP)., [Results] Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2., [Conclusions] These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.

Published
2023

5. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Author

Lakhwani, Sunil, primary, Mateos, María Victoria, additional, Martínez-López, Joaquín, additional, Paiva, Bruno, additional, Rosinol Dachs, Laura, additional, Martínez, Rafael, additional, Oriol, Albert, additional, Bargay, Joan, additional, Gonzalez-Montes, Yolanda, additional, Gironella, Mercedes, additional, Encinas, Cristina, additional, Martin, Jesus, additional, Jarque, Isidro, additional, Granell, Miquel, additional, Abella, Eugenia, additional, García Mateo, Aránzazu, additional, Hernández-Rivas, José Ángel, additional, Ramila, Elena, additional, Krsnik, Isabel, additional, Casado Montero, Luis Felipe, additional, De Arriba, Felipe, additional, Palomera, Luis, additional, Sampol, Antonia, additional, Moraleda, Jose Maria, additional, Casanova, Maria, additional, Delgado, Pilar, additional, Lafuente, Ana, additional, Amutio, Elena, additional, Martínez, Aurelio Lopez, additional, Altés, Albert, additional, Ruíz, M. Ángeles, additional, Lopez-Anglada, Lucia, additional, Bladé Creixenti, Joan, additional, Lahuerta, Juan-José, additional, San-Miguel, Jesús, additional, and Hernández, Miguel-Teodoro, additional

Published
2022
Full Text
View/download PDF

7. Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

Author

Muniesa, Cristina, primary, Gallardo, Fernando, additional, García‐Doval, Ignacio, additional, Estrach, M. Teresa, additional, Combalia, Andrea, additional, Morillo‐Andújar, Mercedes, additional, De la Cruz‐Vicente, Fátima, additional, Machan, Salma, additional, Moya‐Martínez, Cristina, additional, Rovira, Roger, additional, Sanchez‐Gonzalez, Blanca, additional, Acebo, Elvira, additional, Amutio, Elena, additional, Peñate, Yeray, additional, Losada‐Castillo, Maria del Carmen, additional, García‐Muret, M. Pilar, additional, Iznardo, Helena, additional, Román‐Curto, Concepción, additional, Cañueto, Javier, additional, Fernández‐de‐Misa, Ricardo, additional, Flórez, Ángeles, additional, Izu, Rosa María, additional, Torres‐Navarro, Ignacio, additional, Zayas, Ana, additional, Pérez‐Paredes, Gema, additional, Blanes, Mar, additional, Yanguas, J. Ignacio, additional, Pérez‐Ferriols, Amparo, additional, Callejas‐Charavia, Marta, additional, Ortiz‐Romero, Pablo Luis, additional, Pérez‐Gil, Amalia, additional, Prieto‐Torres, Lucia, additional, González‐Barca, Eva, additional, and Servitje, Octavio, additional

Published
2022
Full Text
View/download PDF

9. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Author

Montesinos, Pau, Bergua, Juan M., Vellenga, Edo, Rayón, Chelo, Parody, Ricardo, de la Serna, Javier, León, Angel, Esteve, Jordi, Milone, Gustavo, Debén, Guillermo, Rivas, Concha, González, Marcos, Tormo, Mar, Díaz-Mediavilla, Joaquín, González, Jose D., Negri, Silvia, Amutio, Elena, Brunet, Salut, Lowenberg, Bob, and Sanz, Miguel A.

Published
2009
Full Text
View/download PDF

10. Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.

Author

Muniesa, Cristina, Gallardo, Fernando, García‐Doval, Ignacio, Estrach, M. Teresa, Combalia, Andrea, Morillo‐Andújar, Mercedes, De la Cruz‐Vicente, Fátima, Machan, Salma, Moya‐Martínez, Cristina, Rovira, Roger, Sanchez‐Gonzalez, Blanca, Acebo, Elvira, Amutio, Elena, Peñate, Yeray, Losada‐Castillo, Maria del Carmen, García‐Muret, M. Pilar, Iznardo, Helena, Román‐Curto, Concepción, Cañueto, Javier, and Fernández‐de‐Misa, Ricardo

Subjects
PROGRESSION-free survival, LYMPHOPROLIFERATIVE disorders, MYCOSIS fungoides, T cells, LYMPHOMAS, SEZARY syndrome, CUTANEOUS T-cell lymphoma
Abstract

ABSTRCT: Background: Brentuximab vedotin (BV) has been approved for CD30‐expressing cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Results: Sixty‐seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty‐eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow‐up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow‐up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. Conclusions: These results confirm the efficacy and safety of BV in patients with advanced‐stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Hairy kidney in high-grade B-cell lymphoma

Author

Roldán Galiacho, Verónica, primary, Arzuaga-Méndez, Javier, additional, Fernández-Muñoz, Hemógenes, additional, Imaz Murga, Miren Igone, additional, Amutio, Elena, additional, and García-Ruiz, Juan Carlos, additional

Published
2021
Full Text
View/download PDF

12. Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Author

Sureda, Anna, primary, González, Ana Pilar, additional, Núñez, Javier, additional, Briones, Javier, additional, De la Cruz, Fátima, additional, Eva, Domingo Domenech, additional, Hernandez, Francisca Maria, additional, Terol, María José, additional, Amutio, Elena, additional, Cordoba, Raul, additional, Martínez, Carmen, additional, Moreno, Miriam, additional, Rodriguez Izquierdo, Antonia, additional, Del Campo, Raquel, additional, Greil, Richard, additional, Romero, Samuel, additional, and Garcia-Sanz, Ramón, additional

Published
2021
Full Text
View/download PDF

14. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

Author

de la Serna, Javier, Montesinos, Pau, Vellenga, Edo, Rayón, Chelo, Parody, Ricardo, León, Angel, Esteve, Jordi, Bergua, Juan M., Milone, Gustavo, Debén, Guillermo, Rivas, Concha, González, Marcos, Tormo, Mar, Díaz-Mediavilla, Joaquín, González, Jose D., Negri, Silvia, Amutio, Elena, Brunet, Salut, Lowenberg, Bob, and Sanz, Miguel A.

Published
2008
Full Text
View/download PDF

16. Acquired thrombotic thrombocytopenic Purpura diagnosed during first trimester of pregnancy with excellent outcome after plasma exchange and rituximab, a case report

Author

Arzuaga‐Mendez, Javier, primary, Moreno, Maite, additional, Mateos‐Mazón, Juan J., additional, Vara, Miriam, additional, Dueñas, Marta, additional, Del Orbe, Rafael A., additional, Amutio, Elena, additional, Arrizabalaga, Beatriz, additional, and García‐Ruiz, Juan C., additional

Published
2021
Full Text
View/download PDF

18. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

Author

Sanz, Miguel A., Martín, Guillermo, González, Marcos, León, Angel, Rayón, Chelo, Rivas, Concha, Colomer, Dolors, Amutio, Elena, Capote, Francisco J., Milone, Gustavo A., de la Serna, Javier, Román, José, Barragán, Eva, Bergua, Juan, Escoda, Lourdes, Parody, Ricardo, Negri, Silvia, Calasanz, María J., and Bolufer, Pascual

Published
2004
Full Text
View/download PDF

21. Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Author

Ferra, Christelle M, primary, Perez Encinas, Manuel, additional, Lopez Jimenez, Javier, additional, Ortiz, Macarena, additional, Osorio-Prendes, Santiago, additional, Cordoba, Raul, additional, Ramirez Payer, Angel, additional, González-Barca, Eva, additional, Martín Sánchez, Guillermo, additional, Gonzalez Diaz, Marcos, additional, Sanchez, Maria Jose, additional, Fernandez, Margarita, additional, Baltasar Tello, Patricia, additional, Amutio, Elena, additional, García-Malo, María-Dolores, additional, Vidal Maceñido, Maria Jesus, additional, Fernandez, Pascual, additional, Loscertales, Javier, additional, Rodríguez, Juan Nicolás, additional, Alaez, Concha, additional, Ramroth, Heribert, additional, and Palla, Margarida, additional

Published
2019
Full Text
View/download PDF

24. T‐prolymphocytic leukaemia with sezary‐like morphology.

Author

Roldán Galiacho, Verónica, Arana Berganza, Paula, Amutio, Elena, and García‐Ruiz, Juan Carlos

Subjects
THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, DIFFERENTIAL diagnosis, SEZARY syndrome, TREATMENT effectiveness, LYMPHOCYTIC leukemia, HEMATOPOIETIC stem cell transplantation, CYTOGENETICS
Abstract

A case study of 70-year-old woman is presented who underwent an ambulatory analysis due to peripheral facial paralysis that showed marked lymphocytosis so she was referred to the hospital. Topics include examines on physical examination, the patient had no skin lesions, splenomegaly or lymphadenopathy and the morphological examination of peripheral blood showed a monomorphic lymphoid population small in size with scarce cytoplasm and regular contour.

Published
2023
Full Text
View/download PDF

25. Use of Recombinant Antigens for the Diagnosis of Invasive Candidiasis

Author

Laín, Ana, Elguezabal, Natalia, Amutio, Elena, Fernández de Larrinoa, Iñigo, Moragues, María Dolores, and Pontón, José

Subjects
Article Subject
Abstract

Invasive candidiasis is a frequent and often fatal complication in immunocompromised and critically ill patients. Unfortunately, the diagnosis of invasive candidiasis remains difficult due to the lack of specific clinical symptoms and a definitive diagnostic method. The detection of antibodies against different Candida antigens may help in the diagnosis. However, the methods traditionally used for the detection of antibodies have been based on crude antigenic fungal extracts, which usually show low-reproducibility and cross-reactivity problems. The development of molecular biology techniques has allowed the production of recombinant antigens which may help to solve these problems. In this review we will discuss the usefulness of recombinant antigens in the diagnosis of invasive candidiasis.

Published
2008
Full Text
View/download PDF

26. Use of Recombinant Antigens for the Diagnosis of Invasive Candidiasis

Author

Enfermería, Inmunología, microbiología y parasitología, Química aplicada, Erizaintza, Immunologia, mikrobiologia eta parasitologia, Kimika aplikatua, Laín Torre, Ana, Elguezabal Vega, Natalia María, Amutio, Elena, Fernández de Larrinoa Santamaría, Iñigo, Moragues Tosantos, María Dolores, Pontón, José, Enfermería, Inmunología, microbiología y parasitología, Química aplicada, Erizaintza, Immunologia, mikrobiologia eta parasitologia, Kimika aplikatua, Laín Torre, Ana, Elguezabal Vega, Natalia María, Amutio, Elena, Fernández de Larrinoa Santamaría, Iñigo, Moragues Tosantos, María Dolores, and Pontón, José

Abstract

7 p., Invasive candidiasis is a frequent and often fatal complication in immunocompromised and critically ill patients. Unfortunately, the diagnosis of invasive candidiasis remains difficult due to the lack of specific clinical symptoms and a definitive diagnostic method. The detection of antibodies against different Candida antigens may help in the diagnosis. However, the methods traditionally used for the detection of antibodies have been based on crude antigenic fungal extracts, which usually show low-reproducibility and cross-reactivity problems. The development of molecular biology techniques has allowed the production of recombinant antigens which may help to solve these problems. In this review we will discuss the usefulness of recombinant antigens in the diagnosis of invasive candidiasis.

Published
2008

27. Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens

Author

Montesinos, Pau, primary, Martínez-Cuadrón, David, additional, Rivas, Concha, additional, Brunet, Salut, additional, González-San Miguel, José David, additional, Rubio, Vicente, additional, Pérez, Cristina, additional, Manso, Félix, additional, Sánchez-Godoy, Pedro, additional, Escoda, Lourdes, additional, Amutio, Elena, additional, Zijlmans, Mark, additional, Tormo, Mar, additional, González, Marcos, additional, Rayón, Chelo, additional, Sayas, María José, additional, Ribera, Josep-Maria, additional, Deben, Guillermo, additional, Hernández-Martín, José, additional, Esteve, Jordi, additional, Vellenga, Edo, additional, and Sanz, Miguel, additional

Published
2013
Full Text
View/download PDF

28. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

Author

Sanz, Miguel A., Montesinos, Pau, Vellenga, Edo, Rayón, Consuelo, de la Serna, Javier, Parody, Ricardo, Bergua, Juan M., León, Angel, Negri, Silvia, González, Marcos, Rivas, Concha, Esteve, Jordi, Milone, Gustavo, González, José D., Amutio, Elena, Brunet, Salut, García-Laraña, J., Colomer, Dolors, Calasanz, María J., Chillón, Carmen, Barragán, Eva, Bolufer, Pascual, and Lowenberg, Bob

Published
2008
Full Text
View/download PDF

30. Efficacy and Effectiveness of Azacitidine In Elderly Patients with Acute Myeloid Leukemia and Blasts Counts below 30%: Experience of the Spanish Registry

Author

García, Regina, primary, Arnar, Monserrat, additional, Luño, Elisa, additional, Bargay, Joan, additional, Romero, Ma Mar, additional, Besalduch, Juan, additional, Amutio, Elena, additional, Garrido, Raquel, additional, Carnicero, Fernando, additional, and Smd, Grupo Andaluz de, additional

Published
2010
Full Text
View/download PDF

31. Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.

Author

Montesinos, Pau, primary, Esteve, Jordi, additional, Vellenga, Edo, additional, Rivas, Concha, additional, Brunet, Salut, additional, Arnan, Montserrat, additional, Gonzalez, Jose D., additional, Sanchez, Pedro, additional, Díaz-Mediavilla, Joaquín, additional, Verdeguer, Amparo, additional, Escoda, Lourdes, additional, Amutio, Elena, additional, Rubio, Vicente, additional, Perez, Inmaculada, additional, Guardia, Ramon, additional, Bueno, Javier, additional, Lowenberg, Bob, additional, and Sanz, Miguel A., additional

Published
2009
Full Text
View/download PDF

32. Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.

Author

Ades, Lionel, primary, Montesinos, Pau, additional, Chevret, Sylvie, additional, Vellenga, Edo, additional, Raffoux, Emmanuel, additional, Rayon, Chelo, additional, Díaz-Mediavilla, Joaquim, additional, Thomas, Xavier, additional, Chevallier, Patrice, additional, Rivas, Concha, additional, Guerci, Agnes, additional, Amutio, Elena, additional, Huguet, Francoise, additional, Arias, Jesus, additional, Vey, Norbert, additional, Deben, Guillermo, additional, Meyer, Sandrine, additional, Novo, Andres, additional, Ferrant, Augustin, additional, Bergua, Juan, additional, Rigon, Mathieu Resche, additional, de la Serna, Javier, additional, Dombret, Herve, additional, Castaigne, Sylvie, additional, Fenaux, Pierre, additional, and Sanz, Miguel A., additional

Published
2009
Full Text
View/download PDF

35. Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA).

Author

de la Serna, Javier, primary, Martin, Guillermo, additional, Vellenga, Edo, additional, Rayon, Chelo, additional, Rivas, Concha, additional, Deben, Guillermo, additional, Gonzalez, Marcos, additional, Tormo, Mar, additional, Bergua, Juan, additional, Diaz-Mediavilla, Jaoquin, additional, Leon, Angel, additional, Esteve, Jordi, additional, Parody, Ricardo, additional, Amutio, Elena, additional, Gonzalez, Jose D., additional, Negri, Silvia, additional, Capote, Francisco J., additional, Bueno, Javier, additional, Perez-Encina, Manuel, additional, Novo, Andres, additional, Rodriguez, Antonia, additional, and Sanz, Miguel A., additional

Published
2004
Full Text
View/download PDF

36. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Author

Montesinos, Pau, Bergua, Juan M., Vellenga, Edo, Rayón, Chelo, Parody, Ricardo, de la Serna, Javier, León, Angel, Esteve, Jordi, Milone, Gustavo, Debén, Guillermo, Rivas, Concha, González, Marcos, Tormo, Mar, Díaz-Mediavilla, Joaquín, González, Jose D., Negri, Silvia, Amutio, Elena, Brunet, Salut, Lowenberg, Bob, and Sanz, Miguel A.

Abstract

Differentiation syndrome (DS) can be a life-threatening complication in patients with acute promyelocytic leukemia (APL) undergoing induction therapy with all-transretinoic acid (ATRA). Detailed knowledge about DS has remained limited. We present an analysis of the incidence, characteristics, prognostic factors, and outcome of 739 APL patients treated with ATRA plus idarubicin in 2 consecutive trials (Programa Español de Tratamientos en Hematología [PETHEMA] LPA96 and LPA99). Overall, 183 patients (24.8%) experienced DS, 93 with a severe form (12.6%) and 90 with a moderate form (12.2%). Severe but not moderate DS was associated with an increase in mortality. A bimodal incidence of DS was observed, with peaks occurring in the first and third weeks after the start of ATRA therapy. A multivariate analysis indicated that a WBC count greater than 5 × 109/L and an abnormal serum creatinine level correlated with an increased risk of developing severe DS. Patients receiving systematic prednisone prophylaxis (LPA99 trial) in contrast to those receiving selective prophylaxis with dexamethasone (LPA96 trial) had a lower incidence of severe DS. Patients developing severe DS showed a reduced 7-year relapse-free survival in the LPA96 trial (60% vs 85%, P= .003), but this difference was not apparent in the LPA99 trial (86% vs 88%).

Published
2009
Full Text
View/download PDF

37. Risk-adapted treatment of acute promyelocytic leukemia with all-transretinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

Author

Sanz, Miguel A., Montesinos, Pau, Vellenga, Edo, Rayón, Consuelo, de la Serna, Javier, Parody, Ricardo, Bergua, Juan M., León, Angel, Negri, Silvia, González, Marcos, Rivas, Concha, Esteve, Jordi, Milone, Gustavo, González, José D., Amutio, Elena, Brunet, Salut, García-Laraña, J., Colomer, Dolors, Calasanz, María J., Chillón, Carmen, Barragán, Eva, Bolufer, Pascual, and Lowenberg, Bob

Abstract

A previous report of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) Group showed that a risk-adapted strategy combining all-transretinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia results in an improved outcome. Here we analyze treatment outcome of an enlarged series of patients who have been followed up for a median of 65 months. From November 1999 through July 2005 (LPA99 trial), 560 patients received induction therapy with ATRA plus idarubicin. Patients achieving complete remission received 3 courses of consolidation followed by maintenance with ATRA and low-dose chemotherapy. The 5-year cumulative incidence of relapse and disease-free survival were 11% and 84%, respectively. These results compare favorably with those obtained in the previous LPA96 study (P= .019 and P= .04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy.

Published
2008
Full Text
View/download PDF

38. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-transretinoic acid and idarubicin

Author

de la Serna, Javier, Montesinos, Pau, Vellenga, Edo, Rayón, Chelo, Parody, Ricardo, León, Angel, Esteve, Jordi, Bergua, Juan M., Milone, Gustavo, Debén, Guillermo, Rivas, Concha, González, Marcos, Tormo, Mar, Díaz-Mediavilla, Joaquín, González, Jose D., Negri, Silvia, Amutio, Elena, Brunet, Salut, Lowenberg, Bob, and Sanz, Miguel A.

Abstract

An understanding of the prognostic factors associated with the various forms of induction mortality in patients with acute promyelocytic leukemia (APL) has remained remarkably limited. This study reports the incidence, time of occurrence, and prognostic factors of the major categories of induction failure in a series of 732 patients of all ages (range, 2-83 years) with newly diagnosed APL who received all-transretinoic acid (ATRA) plus idarubicin as induction therapy in 2 consecutive studies of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) Group. Complete remission was attained in 666 patients (91%). All the 66 induction failures were due to induction death. Hemorrhage was the most common cause of induction death (5%), followed by infection (2.3%) and differentiation syndrome (1.4%). Multivariate analysis identified specific and distinct pretreatment characteristics to correlate with an increased risk of death caused by hemorrhage (abnormal creatinine level, increased peripheral blast counts, and presence of coagulopathy), infection (age >60 years, male sex, and fever at presentation), and differentiation syndrome (Eastern Cooperative Oncology Group [ECOG] score >1 and low albumin levels), respectively. These data furnish clinically relevant information that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL.

Published
2008
Full Text
View/download PDF

39. All-transretinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

Author

Sanz, Miguel A., Vellenga, Edo, Rayón, Chelo, Díaz-Mediavilla, Joaquín, Rivas, Concha, Amutio, Elena, Arias, Jesús, Debén, Guillermo, Novo, Andrés, Bergua, Juan, de la Serna, Javier, Bueno, Javier, Negri, Silvia, Beltrán de Heredia, José M., and Martín, Guillermo

Abstract

Therapeutic results in elderly patients with acute promyelocytic leukemia (APL) have been generally reported as less effective than for younger patients. Patients 60 years or older with APL who were enrolled in 2 successive multicenter PETHEMA studies received induction therapy with all-transretinoic acid (ATRA) and idarubicin, consolidation with 3 anthracycline monochemotherapy courses with or without ATRA, and maintenance with ATRA and low-dose chemotherapy. Eighty-seven of 104 patients achieved complete remission (84%). Eighty-six proceeded to consolidation therapy (2 withdrew after the first and second courses). Deaths in remission occurred during consolidation and maintenance therapy in 3 and 4 patients, respectively. One patient showed molecular persistence after consolidation and 5 had a relapse. The 6-year cumulative incidence of relapse, leukemia-free survival, and disease-free survival were 8.5%, 91%, and 79%, respectively. A significantly higher incidence of low-risk patients found among the elderly, as compared to younger patients, may partially account for the low relapse rate observed. This study confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of protocols using ATRA and anthracycline monochemotherapy for induction and consolidation therapy in elderly patients.

Published
2004
Full Text
View/download PDF

40. Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.

Author

Cervera, Jose, Martin, Guillermo, Hernandez, Jesus M., Vellenga, Edo, Calasanz, Maria J., Martinez-Climent, Jose A., Luño, Elisa, Ferro, Maria T., Rayon, Consuelo, Gonzalez, Marcos, Tormo, Mar, Rivas, Concha, Amutio, Elena, de la Serna, Javier, Gonzalez-San Miguel, Jose D., Bergua, Juan, Leon, Angel, Diaz-Mediavilla, Joaquin, Garcia-Laraña, Jose, Esteve, Jordi, and Sanz, Miguel A.

Published
2004
Full Text
View/download PDF

41. Binucleated Lymphocytes With Globular Inclusions in Relapsed Splenic Marginal Zone Lymphoma.

Author

Roldán Galiacho, Verónica, Dueñas Usategui, Marta, Alonso Varela, Marta, Amutio, Elena, and García‐Ruiz, Juan Carlos

Subjects
*BLOOD cell count, *MUCOSA-associated lymphoid tissue lymphoma, *LEUKOCYTE count, *B cells, *LYMPHOCYTE count
Abstract

This article discusses a case of an 84-year-old man with relapsed splenic marginal zone lymphoma. The patient experienced a rapid increase in lymphocyte count and associated cytopenias. Peripheral blood smear showed binucleated lymphocytes with globular inclusions, a rare finding in splenic marginal zone lymphoma. The patient was treated with oral cyclophosphamide due to his age and comorbidities. This case highlights the importance of integrating morphology and immunophenotype in diagnosing splenic marginal zone lymphoma and the rare occurrence of binucleated lymphocytes with globular inclusions in this condition. [Extracted from the article]

Published
2024
Full Text
View/download PDF

43. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Author

Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, and Sanz MA

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Child, Preschool, Chromosomes, Human, Pair 15 genetics, Chromosomes, Human, Pair 17 genetics, Cohort Studies, Female, Follow-Up Studies, Humans, In Situ Hybridization, Fluorescence, Leukemia, Promyelocytic, Acute pathology, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Oncogene Proteins, Fusion genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Remission Induction, Reverse Transcriptase Polymerase Chain Reaction, Survival Rate, Translocation, Genetic, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Chromosome Aberrations, Leukemia, Promyelocytic, Acute drug therapy, Leukemia, Promyelocytic, Acute genetics, Tretinoin therapeutic use
Abstract

Background: Acute promyelocytic leukemia is a subtype of acute myeloid leukemia characterized by the t(15;17). The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter., Design and Methods: Based on cytogenetic data available for 495 patients with acute promyelocytic leukemia enrolled in two consecutive PETHEMA trials (LPA96 and LPA99), we analyzed the incidence, characteristics, and outcome of patients with acute promyelocytic leukemia with and without additional chromosomal abnormalities who had been treated with all-trans retinoic acid plus anthracycline monochemotherapy for induction and consolidation., Results: Additional chromosomal abnormalities were observed in 140 patients (28%). Trisomy 8 was the most frequent abnormality (36%), followed by abn(7q) (5%). Patients with additional chromosomal abnormalities more frequently had coagulopathy (P=0.03), lower platelet counts (P=0.02), and higher relapse-risk scores (P=0.02) than their counterparts without additional abnormalities. No significant association with FLT3/ITD or other clinicopathological characteristics was demonstrated. Patients with and without additional chromosomal abnormalities had similar complete remission rates (90% and 91%, respectively). Univariate analysis showed that additional chromosomal abnormalities were associated with a lower relapse-free survival in the LPA99 trial (P=0.04), but not in the LPA96 trial. However, neither additional chromosomal abnormalities overall nor any specific abnormality was identified as an independent risk factor for relapse in multivariate analysis., Conclusions: The lack of independent prognostic value of additional chromosomal abnormalities in acute promyelocytic leukemia does not support the use of alternative therapeutic strategies when such abnormalities are found.

Published
2010
Full Text
View/download PDF

44. [Invasive fungal infection in immunocompromised patients].

Author

García-Ruiz JC, Amutio E, and Pontón J

Subjects
HIV Infections complications, Humans, Mycoses epidemiology, Mycoses etiology, Neoplasms complications, Organ Transplantation adverse effects, Immunocompromised Host, Mycoses immunology
Abstract

At present, the concept of immunocompromised patient cannot be applied exclusively to the classic groups of cancer, HIV-infected or transplanted patients. The cytotoxic treatment of patients with much more common conditions such as asthma, inflammatory bowel disease or rheumatoid arthritis has produced an exponential increase in the universe of patients with different degrees of immunological commitment. The generalization of transplantation procedures, even in advanced ages of life, the prolonged survival of patients with cancer and the decrease of the viral load in HIV-infected patients have resulted in long-term immunosupresions. The prevalence of invasive fungal infections (IFIs) is increasing in immunocompromised patients but each group of immunocompromised patients present peculiarities that must be recognized to be addressed appropriately. Despite the recent advances in the diagnosis and treatment of IFIs, they still present unacceptable morbility and mortality rates. Although IFIs are commonly caused by Candida spp. or Aspergillus spp., a variety of fungi are emerging as agents of IFIs. These emerging fungi require an individualized basic and clinical study. The aim of this work is to review the IFIs caused by common and emerging fungi in the three more numerous groups of immunocompromised patients: HIV-infected patients, solid organ transplant recipients and cancer patients, especially those with hematological malignancies or hematopoietic stem-cell transplantation.

Published
2004

45. [Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis].

Author

Moragues MD, Ortiz N, Iruretagoyena JR, García-Ruiz JC, Amutio E, Rojas A, Mendoza J, Quindós G, and Pontón-San Emeterio J

Subjects
Adolescent, Adult, Aged, Antigens, Fungal immunology, Candida classification, Candida albicans immunology, Candidiasis microbiology, Disease Susceptibility, Female, Fungemia microbiology, Humans, Male, Middle Aged, Mycelium immunology, Postoperative Complications diagnosis, Postoperative Complications microbiology, Retrospective Studies, Sensitivity and Specificity, Serologic Tests methods, Antibodies, Fungal blood, Candida immunology, Candidiasis diagnosis, Fluorescent Antibody Technique, Indirect, Fungemia diagnosis, Reagent Kits, Diagnostic
Abstract

Introduction: Two tests for the detection of antibodies to Candida albicans germ tubes in patients with invasive candidiasis were compared: a new commercially available test (Candida albicans IFA IgG) and the indirect immunofluorescence test generally used for this purpose., Methods: With the use of two indirect immunofluorescence tests, retrospective study was done on 172 sera from 51 patients classified into two groups: Group I included 123 serum samples from 32 patients with invasive candidiasis, and Group II, the control, included 49 serum samples from 19 patients with no evidence of Candida infection., Results: In Group I, 84% of patients presented anti-germ tube antibody titers >or= 1:160 by the Candida albicans IFA IgG test and 78.1% of patients were positive by the generally used test. There was a high correlation between the two tests (R2 =0.9512 by patients; R2 = 0.8986 by sera). When a titer value of >or= 1:160 was used as cutoff, the Candida albicans IFA IgG test showed a sensitivity of 84.4% and a specificity of 94.7%, whereas the traditional test showed a sensitivity of 78.1% and a specificity of 100%., Conclusions: The commercially available Candida albicans IFA IgG test is similar to the test generally used for the detection of antibodies to C. albicans germ tubes and provides faster and easier diagnosis of invasive candidiasis in the clinical microbiology laboratory.

Published
2004
Full Text
View/download PDF

46. [Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis].

Author

Moragues MD, Amutio E, García-Ruiz JC, and Pontón J

Subjects
Antifungal Agents therapeutic use, Aspergillosis blood, Aspergillosis drug therapy, Aspergillosis etiology, Aspergillus immunology, Aspergillus isolation & purification, Biomarkers, Follow-Up Studies, Fungemia drug therapy, Fungemia etiology, Galactose analogs & derivatives, Humans, Immunocompromised Host, Neutropenia complications, Patient Isolators, Predictive Value of Tests, Retrospective Studies, Risk, Sensitivity and Specificity, Time Factors, Antigens, Fungal blood, Aspergillosis diagnosis, Enzyme-Linked Immunosorbent Assay, Fungemia diagnosis, Mannans blood
Abstract

The usefulness of galactomannan detection using the Platelia Aspergillus test for the diagnosis of invasive aspergillosis was studied in 849 sera from 54 hematological patients with prolonged neutropenia, which were classified according to the risk for invasive aspergillosis. Three patients developed a proven invasive aspergillosis, one a probable invasive aspergillosis and 17 patients a possible invasive aspergillosis. Thirty-three patients showed no evidence of invasive aspergillosis. All patients with proven invasive aspergillosis had a high risk for invasive aspergillosis, while the one having probable invasive aspergillosis had intermediate risk. Detection of galactomannan in this study showed a sensitivity of 66.7% for patients with proven invasive aspergillosis and 50% for patients with proven and probable invasive aspergillosis. The specificity was 98% or higher in all groups studied. The predictive positive and negative values for patients with proven invasive aspergillosis were 66.7% and 98%, respectively. A rise in the concentration of galactomannan was observed in patients who failed to respond to the antifungal treatment. Galactomannan antigenemia preceded post-mortem histological diagnosis of invasive aspergillosis in two patients by 17 and 81 days, respectively. In conclusion, detection of galactomannan by the Platelia Aspergillus test allows for a specific and relatively sensitive diagnosis of invasive aspergillosis in hematological patients with a high and intermediate risk for invasive aspergillosis.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results